Weaver Capital Management LLC Trims Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Weaver Capital Management LLC decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.3% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,335 shares of the biopharmaceutical company’s stock after selling 46 shares during the quarter. Weaver Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $847,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Pinney & Scofield Inc. purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $25,000. OFI Invest Asset Management purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $28,000. Rakuten Securities Inc. raised its position in Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 15 shares during the period. Tompkins Financial Corp purchased a new stake in Regeneron Pharmaceuticals in the first quarter valued at $32,000. Finally, Curat Global LLC purchased a new stake in Regeneron Pharmaceuticals in the first quarter valued at $32,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Morgan Stanley reduced their target price on Regeneron Pharmaceuticals from $958.00 to $755.00 and set an “overweight” rating on the stock in a research report on Monday, June 2nd. Cantor Fitzgerald assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $695.00 target price on the stock. Canaccord Genuity Group raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 22nd. JPMorgan Chase & Co. dropped their price objective on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an “overweight” rating for the company in a research note on Monday, June 9th. Finally, BMO Capital Markets dropped their price objective on Regeneron Pharmaceuticals from $800.00 to $600.00 and set an “outperform” rating for the company in a research note on Monday, June 2nd. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $836.48.

Regeneron Pharmaceuticals Trading Down 0.8%

REGN opened at $509.72 on Friday. The stock has a market capitalization of $55.03 billion, a price-to-earnings ratio of 12.98, a PEG ratio of 1.88 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. The business has a fifty day moving average price of $558.34 and a 200 day moving average price of $641.68. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to analysts’ expectations of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The firm’s quarterly revenue was down 3.7% on a year-over-year basis. During the same period last year, the firm earned $9.55 earnings per share. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.69%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.